pharmaphorum

FDA starts review of Summit's VEGFxPD-1 bispecific

Summit Therapeutics has moved ahead in the race to bring a therapy targeting both VEGF and PD- (L)1 to market, after the FDA ...
GlobalData on MSN

Akeso’s PD-1/CTLA-4 bispecific trumps chemo in frontline gastric cancer

Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...
Medindia

Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer

Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO G I), comparing cadonilimab ...
Targeted Oncology

PD-1–Based Neoadjuvant Therapy Benefits Select Patients With pMMR Rectal Cancer

A novel neoadjuvant therapy combining PD-1 blockade and chemoradiotherapy shows promising results in treating advanced rectal ...

PD-1 Resistant Head and Neck Cancer Market Research 2026 - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The market opportunities in the PD-1 Resistant Head and Neck Cancer sector include the rising need for salvage therapies due to resistance to standard treatments, the proliferation of next-gen ...